OptimizeRx (NASDAQ:OPRX) Research Coverage Started at Stephens

Stephens began coverage on shares of OptimizeRx (NASDAQ:OPRX) in a research report released on Friday, Marketbeat reports. The brokerage issued an equal weight rating and a $5.50 price target on the stock.

A number of other analysts also recently issued reports on the stock. Barclays dropped their price objective on shares of OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a report on Thursday, November 14th. Royal Bank of Canada cut their price objective on OptimizeRx from $14.00 to $7.00 and set an “outperform” rating for the company in a report on Thursday, November 14th. William Blair reissued an “outperform” rating on shares of OptimizeRx in a report on Thursday, November 14th. Roth Mkm reaffirmed a “buy” rating and issued a $16.00 target price (down previously from $20.00) on shares of OptimizeRx in a research note on Thursday, November 14th. Finally, JMP Securities reduced their price target on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 14th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $9.71.

OptimizeRx Trading Up 3.4 %

Shares of OPRX opened at $4.91 on Friday. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.23 and a quick ratio of 3.23. OptimizeRx has a 1-year low of $3.78 and a 1-year high of $16.65. The company has a market capitalization of $90.45 million, a P/E ratio of -3.69 and a beta of 1.34. The firm’s 50 day simple moving average is $5.37 and its 200 day simple moving average is $7.80.

Insider Buying and Selling

In other news, CEO William J. Febbo purchased 20,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average cost of $5.01 per share, for a total transaction of $100,200.00. Following the acquisition, the chief executive officer now directly owns 601,253 shares of the company’s stock, valued at $3,012,277.53. This represents a 3.44 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 6.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On OptimizeRx

Hedge funds have recently modified their holdings of the company. Barclays PLC raised its position in OptimizeRx by 358.5% during the 3rd quarter. Barclays PLC now owns 26,934 shares of the company’s stock valued at $208,000 after purchasing an additional 21,060 shares during the last quarter. Bullseye Asset Management LLC increased its stake in shares of OptimizeRx by 55.6% during the third quarter. Bullseye Asset Management LLC now owns 214,046 shares of the company’s stock valued at $1,652,000 after buying an additional 76,458 shares during the period. BNP Paribas Financial Markets raised its holdings in shares of OptimizeRx by 189.2% during the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after acquiring an additional 2,414 shares in the last quarter. Quest Partners LLC lifted its stake in OptimizeRx by 15,965.6% in the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after acquiring an additional 9,739 shares during the period. Finally, Greenwood Capital Associates LLC lifted its stake in OptimizeRx by 8.0% in the third quarter. Greenwood Capital Associates LLC now owns 67,356 shares of the company’s stock worth $520,000 after acquiring an additional 4,999 shares during the period. Hedge funds and other institutional investors own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.